Head-to-head evidence
Abp 234 vs Camrelizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Abp 234
Developed by Amgen
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06430866 (registry estimate)
Camrelizumab
Developed by Jiangsu Hengrui Pharmaceuticals
NCT03134872 · Phase 3 · completed
The study randomly assigned 419 participants to treatment or an active chemotherapy comparator, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Abp 234's landscape · Camrelizumab's landscape